Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors

被引：0
|
作者：
Kettner, Nicole M. [1 ]
Bui, Tuyen N. [1 ]
Navarro-Yepes, Juliana [1 ]
Eckols, T. Kris [1 ]
Raghavendra, Akshara S. [1 ]
Tweardy, David J. [1 ]
Hunt, Kelly K. [1 ]
Tripathy, Debu [1 ]
Keyomarsi, Khandan [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1774
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Treatment Strategy for Patients with HR-Positive HER2-Negative Metastatic Breast Cancer That Progressed on CDK4/6 Inhibitors
    Hayama, Shouko
    Nakamura, Rikiya
    Miyaki, Toshiko
    Itami, Makiko
    Yamamoto, Naohito
    BREAST CARE, 2022, 17 (01) : 16 - 23
  • [2] CDK4/6 inhibitors for primary endocrine resistant HR-positive/ HER2-negative metastatic breast cancer: a case report
    Luo, Ting
    Zhu, Kunrui
    Zhong, Xiaorong
    He, Ping
    Yan, Xi
    Tian, Tinglun
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [3] HR-positive, HER2-negative Breast Cancer Prolongation of Survival by the CDK4 & 6 Inhibitor Abemaciclib
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (12) : 690 - 691
  • [4] Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors
    Onder, Tugba
    Ate, Ozturk
    Oner, Rem
    Karacin, Cengiz
    CLINICAL BREAST CANCER, 2024, 24 (06) : 519 - 526
  • [5] CDK4/6 inhibitors in HR-positive breast cancer immunotherapy
    Shen, Mimi
    Ma, Zhiyuan
    Zhu, Jiaxing
    Wen, Guorong
    Jin, Hai
    An, Jiaxing
    Tuo, Biguang
    Liu, Xuemei
    Li, Taolang
    BIOORGANIC CHEMISTRY, 2025, 154
  • [6] Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
    Rossi, Lorenzo
    McCartney, Amelia
    Risi, Emanuela
    Malorni, Luca
    Biganzoli, Laura
    Di Leo, Angelo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [7] Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Zattarin, Emma
    Presti, Daniele
    Mariani, Luigi
    Sposetti, Caterina
    Leporati, Rita
    Menichetti, Alice
    Corti, Chiara
    Benvenuti, Chiara
    Fuca, Giovanni
    Lobefaro, Riccardo
    Ligorio, Francesca
    Provenzano, Leonardo
    Vingiani, Andrea
    Del Vecchio, Marta
    Griguolo, Gaia
    Sirico, Marianna
    Bernocchi, Ottavia
    Marra, Antonio
    Zagami, Paola
    Agostinetto, Elisa
    Jacobs, Flavia
    Di Mauro, Pierluigi
    Esposito, Andrea
    Giorgi, Carlo Alberto
    Lalli, Luca
    Boldrini, Laura
    Giacchetti, Pier Paolo Berton
    Schianca, Ambra Carnevale
    Guarneri, Valentina
    Pedersini, Rebecca
    Losurdo, Agnese
    Zambelli, Alberto
    Generali, Daniele
    Criscitiello, Carmen
    Curigliano, Giuseppe
    Pruneri, Giancarlo
    de Braud, Filippo
    Dieci, Maria Vittoria
    Vernieri, Claudio
    NPJ BREAST CANCER, 2023, 9 (01)
  • [8] Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Emma Zattarin
    Daniele Presti
    Luigi Mariani
    Caterina Sposetti
    Rita Leporati
    Alice Menichetti
    Chiara Corti
    Chiara Benvenuti
    Giovanni Fucà
    Riccardo Lobefaro
    Francesca Ligorio
    Leonardo Provenzano
    Andrea Vingiani
    Marta Del Vecchio
    Gaia Griguolo
    Marianna Sirico
    Ottavia Bernocchi
    Antonio Marra
    Paola Zagami
    Elisa Agostinetto
    Flavia Jacobs
    Pierluigi Di Mauro
    Andrea Esposito
    Carlo Alberto Giorgi
    Luca Lalli
    Laura Boldrini
    Pier Paolo Berton Giacchetti
    Ambra Carnevale Schianca
    Valentina Guarneri
    Rebecca Pedersini
    Agnese Losurdo
    Alberto Zambelli
    Daniele Generali
    Carmen Criscitiello
    Giuseppe Curigliano
    Giancarlo Pruneri
    Filippo de Braud
    Maria Vittoria Dieci
    Claudio Vernieri
    npj Breast Cancer, 9
  • [9] Management of HR-positive, HER2-negative advanced breast cancer with CDK4/6 inhibitors: Effect of online education on clinician knowledge, competence and confidence
    Fisher, G.
    Middleton, D.
    Day, C.
    Di Leo, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S102 - S102
  • [10] Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer
    Imamovic, Elma
    Veledar, Anisa
    Kalic, Zerina
    Softic, Adna
    Mrdanovic, Emina
    Smajlhodzic-Deljo, Merima
    MEDICON 2023 AND CMBEBIH 2023, VOL 1, 2024, 93 : 345 - 350
12345